Aventis Diabetes Outlook: Lantus Has Brighter Future Than Exubera, Firm Says
Executive Summary
Aventis expects the long-acting insulin Lantus will be a bigger product than Exubera (inhaled insulin) in the diabetes market, Management Board Chairman Igor Landau maintained
You may also be interested in...
Aventis Defense Against Sanofi: Strong Pipeline Or Irrational “Exubera-nce”?
Aventis is using the prospects of Genasense as its first line of defense against Sanofi's hostile takeover bid
Aventis Defense Against Sanofi: Strong Pipeline Or Irrational “Exubera-nce”?
Aventis is using the prospects of Genasense as its first line of defense against Sanofi's hostile takeover bid
Exubera May Be Wild Card In Sanofi Bid For Aventis; Genta Deal Unaffected
Aventis' share of the Phase III inhaled insulin Exubera is one of the wild cards that could come into play as a result of Sanofi's hostile takeover bid for the company